Citigroup
APLS

Citigroup’s Apellis Pharmaceuticals APLS Stock Holding History

Citigroup’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-29,000
Closed -$925K – 5554
2024
Q4 		$925K Buy
+29,000
New +$872K ﹤0.01% 3419
2024
Q2 		– Sell
-89,700
Closed -$5.27M – 5569
2024
Q1 		$5.27M Buy
+89,700
New +$5.72M ﹤0.01% 1674
2023
Q4 		– Sell
-30,000
Closed -$1.14M – 5682
2023
Q3 		$1.14M Buy
30,000
+10,000
+50% +$439K ﹤0.01% 2397
2023
Q2 		$1.82M Sell
20,000
-4,900
-20% -$423K ﹤0.01% 2307
2023
Q1 		$1.64M Buy
24,900
+200
+0.8% +$11.5K ﹤0.01% 2157
2022
Q4 		$1.28M Sell
24,700
-10,300
-29% -$546K ﹤0.01% 2398
2022
Q3 		$2.39M Buy
35,000
+29,400
+525% +$1.74M ﹤0.01% 2022
2022
Q2 		$253K Sell
5,600
-6,600
-54% -$301K ﹤0.01% 3706
2022
Q1 		$620K Buy
+12,200
New +$539K ﹤0.01% 3357

Other funds holding APLS

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Citigroup's APLS Position: Q2 2026 in Review

Citigroup sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 657,223 shares — an estimated $26.4M sold.

Citigroup first reported a position in APLS in Q4 2017 and held it in 34 quarters. The position peaked at $26.4M in Q1 2026. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.

  • Citigroup reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Citigroup sold 657,223 Apellis Pharmaceuticals shares in Q2 2026, an estimated $26.4M.
  • Citigroup first reported a position in Apellis Pharmaceuticals in Q4 2017 and held it in 34 quarters.
  • Citigroup's Apellis Pharmaceuticals position peaked at $26.4M in Q1 2026.
  • 1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.